|
Company Watch
Lupin Acquires Rubamin Labs
Our news Bureau - Mumbai
 Lupin
has announced the acquisition of Rubamin Laboratories (RLL), the pharmaceuticals
arm of the Rubamin Group, for an undisclosed amount. The company is a 100 percent
EOU, primarily engaged in R&D services and manufacture of advanced intermediates
for APIs under the contract research and manufacturing model (CRAMS). Rubamin
can partner with innovators at different stages of its drug development processes
from pre-clinical to Phase I-III trials, and later for commercial supply of
intermediates.
RLL is a research driven organisation with 145 employees, of which 30 percent
are involved in R&D. The company's R&D capabilities encompass activities
such as product development and optimization, and NCE development support. The
company caters to innovator and generics manufacturing companies in India and
overseas. RLL's strong customer base, spread across US and Europe, enables Lupin
to move a step forward in its efforts to achieve global presence in the CRAMS
segment.
RLL's manufacturing facility near Vadodara, Gujarat, is capable
of delivering small volumes (upto 50 kgs) from its pilot plant and multi-tonne
quantities from its multipurpose plants. The company has a kilo lab to manufacture
small volumes of high value intermediates. RLL also offers a range of products—aryl
piperazines, benzimidazoles, benzophenones, benzhydryl compounds, imidazoles,
triazoles, indanones and related compounds, quiniloline derivatives, chloroethanolamine
salts and other fine chemicals.
This acquisition would provide Lupin access to RLL's customer base of innovator
and generic companies in the US and Europe, and various technology platforms,
which Lupin does not have. Lupin would also be able to use this customer base,
and technology platforms to leverage its own CRAMS initiatives. The company
will also fill gaps, which RLL has in terms of scale-up and forward integration.
Apart from this, Lupin is expected to initiate operational restructuring to
reduce costs and improve profitability.
|
